Live feed16:00:53·1115dPRReleasevia QuantisnowUltragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)ByQuantisnow·Wall Street's wire, on your screen.MREO· Mereo BioPharma Group plcRARE· Ultragenyx Pharmaceutical Inc.Health Care
